Summary of EGFR-Biomarker data from the randomized, controlled phase 3 trial SQUIRE on adding Necitumumab to first-line Gemcitabine-Cisplatin (GC) for squamous Non-Small Cell Lung Cancer (sqNSCLC).
Year: 2017
Type: article
Authors: Christian Schumann, Martin Reck, Mark Thomas, J. Mezger, Mark A. Socinski, Rebecca R. Hozak, H. Depenbrock, T Krause, W. Hirsch, Nick Thatcher
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W2761452170